Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study.

@article{Englisch2018NeurocognitiveEO,
  title={Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study.},
  author={Susanne Englisch and Hanna Sophie Jung and Sarah Eisenacher and Antje Lewien and Anna Becker and Ulrike Nowak and Hanna Braun and Jascha Thiem and Andreas Meyer-Lindenberg and Mathias Zink},
  journal={Journal of clinical psychopharmacology},
  year={2018},
  volume={38 4},
  pages={
          357-361
        }
}
BACKGROUND Cognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may therefore have the potential of improving neurocognition in… CONTINUE READING